Sean Wieland
Stock Analyst at Piper Sandler
(1.43)
# 2,903
Out of 4,818 analysts
29
Total ratings
40%
Success rate
-0.1%
Average return
Main Sectors:
Stocks Rated by Sean Wieland
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRVA Privia Health Group | Maintains: Overweight | $25 → $40 | $23.39 | +71.01% | 2 | Feb 28, 2025 | |
| OMCL Omnicell | Upgrades: Overweight | $70 → $39 | $30.67 | +27.18% | 11 | Nov 3, 2023 | |
| AMWL American Well | Maintains: Overweight | $100 → $120 | $7.71 | +1,456.42% | 2 | Jun 23, 2022 | |
| HIMS Hims & Hers Health | Maintains: Overweight | $8 → $6 | $26.71 | -77.54% | 3 | May 26, 2022 | |
| DOCS Doximity | Maintains: Overweight | $81 → $44 | $54.22 | -18.85% | 2 | May 19, 2022 | |
| IQV IQVIA Holdings | Maintains: Neutral | $261 → $231 | $147.06 | +57.08% | 4 | Feb 18, 2022 | |
| TDOC Teladoc Health | Maintains: Overweight | $305 → $291 | $7.07 | +4,015.98% | 5 | Feb 25, 2021 |
Privia Health Group
Feb 28, 2025
Maintains: Overweight
Price Target: $25 → $40
Current: $23.39
Upside: +71.01%
Omnicell
Nov 3, 2023
Upgrades: Overweight
Price Target: $70 → $39
Current: $30.67
Upside: +27.18%
American Well
Jun 23, 2022
Maintains: Overweight
Price Target: $100 → $120
Current: $7.71
Upside: +1,456.42%
Hims & Hers Health
May 26, 2022
Maintains: Overweight
Price Target: $8 → $6
Current: $26.71
Upside: -77.54%
Doximity
May 19, 2022
Maintains: Overweight
Price Target: $81 → $44
Current: $54.22
Upside: -18.85%
IQVIA Holdings
Feb 18, 2022
Maintains: Neutral
Price Target: $261 → $231
Current: $147.06
Upside: +57.08%
Teladoc Health
Feb 25, 2021
Maintains: Overweight
Price Target: $305 → $291
Current: $7.07
Upside: +4,015.98%